High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)

High-dose prednisolone may not be superior to a low-dose 6-week regimen in improving clinical, physiological and radiological outcomes, or health-related quality of life, in patients with symptomatic post-COVID-19 diffuse parenchymal lung abnormalities https://bit.ly/32zqnXt

Detalles Bibliográficos
Autores principales: Dhooria, Sahajal, Chaudhary, Shivani, Sehgal, Inderpaul Singh, Agarwal, Ritesh, Arora, Siddhant, Garg, Mandeep, Prabhakar, Nidhi, Puri, Goverdhan Dutt, Bhalla, Ashish, Suri, Vikas, Yaddanapudi, Lakshmi Narayana, Muthu, Valliappan, Prasad, Kuruswamy Thurai, Aggarwal, Ashutosh Nath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850687/
https://www.ncbi.nlm.nih.gov/pubmed/34887325
http://dx.doi.org/10.1183/13993003.02930-2021
_version_ 1784652653964296192
author Dhooria, Sahajal
Chaudhary, Shivani
Sehgal, Inderpaul Singh
Agarwal, Ritesh
Arora, Siddhant
Garg, Mandeep
Prabhakar, Nidhi
Puri, Goverdhan Dutt
Bhalla, Ashish
Suri, Vikas
Yaddanapudi, Lakshmi Narayana
Muthu, Valliappan
Prasad, Kuruswamy Thurai
Aggarwal, Ashutosh Nath
author_facet Dhooria, Sahajal
Chaudhary, Shivani
Sehgal, Inderpaul Singh
Agarwal, Ritesh
Arora, Siddhant
Garg, Mandeep
Prabhakar, Nidhi
Puri, Goverdhan Dutt
Bhalla, Ashish
Suri, Vikas
Yaddanapudi, Lakshmi Narayana
Muthu, Valliappan
Prasad, Kuruswamy Thurai
Aggarwal, Ashutosh Nath
author_sort Dhooria, Sahajal
collection PubMed
description High-dose prednisolone may not be superior to a low-dose 6-week regimen in improving clinical, physiological and radiological outcomes, or health-related quality of life, in patients with symptomatic post-COVID-19 diffuse parenchymal lung abnormalities https://bit.ly/32zqnXt
format Online
Article
Text
id pubmed-8850687
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-88506872022-02-18 High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial) Dhooria, Sahajal Chaudhary, Shivani Sehgal, Inderpaul Singh Agarwal, Ritesh Arora, Siddhant Garg, Mandeep Prabhakar, Nidhi Puri, Goverdhan Dutt Bhalla, Ashish Suri, Vikas Yaddanapudi, Lakshmi Narayana Muthu, Valliappan Prasad, Kuruswamy Thurai Aggarwal, Ashutosh Nath Eur Respir J Agora High-dose prednisolone may not be superior to a low-dose 6-week regimen in improving clinical, physiological and radiological outcomes, or health-related quality of life, in patients with symptomatic post-COVID-19 diffuse parenchymal lung abnormalities https://bit.ly/32zqnXt European Respiratory Society 2022-02-17 /pmc/articles/PMC8850687/ /pubmed/34887325 http://dx.doi.org/10.1183/13993003.02930-2021 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Agora
Dhooria, Sahajal
Chaudhary, Shivani
Sehgal, Inderpaul Singh
Agarwal, Ritesh
Arora, Siddhant
Garg, Mandeep
Prabhakar, Nidhi
Puri, Goverdhan Dutt
Bhalla, Ashish
Suri, Vikas
Yaddanapudi, Lakshmi Narayana
Muthu, Valliappan
Prasad, Kuruswamy Thurai
Aggarwal, Ashutosh Nath
High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)
title High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)
title_full High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)
title_fullStr High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)
title_full_unstemmed High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)
title_short High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)
title_sort high-dose versus low-dose prednisolone in symptomatic patients with post-covid-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the coldster trial)
topic Agora
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850687/
https://www.ncbi.nlm.nih.gov/pubmed/34887325
http://dx.doi.org/10.1183/13993003.02930-2021
work_keys_str_mv AT dhooriasahajal highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT chaudharyshivani highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT sehgalinderpaulsingh highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT agarwalritesh highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT arorasiddhant highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT gargmandeep highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT prabhakarnidhi highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT purigoverdhandutt highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT bhallaashish highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT surivikas highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT yaddanapudilakshminarayana highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT muthuvalliappan highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT prasadkuruswamythurai highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial
AT aggarwalashutoshnath highdoseversuslowdoseprednisoloneinsymptomaticpatientswithpostcovid19diffuseparenchymallungabnormalitiesanopenlabelrandomisedtrialthecoldstertrial

Ejemplares similares